FDA Clears PrecivityAD2 Blood Test for Alzheimer's (Ages 40+)

C2N Diagnostics' PrecivityAD2 received FDA clearance for amyloid detection in adults as young as 40, a regulatory milestone that adds to the growing arsenal of accessible blood-based diagnostics. This complements Roche's pTau181 and reinforces the rapid expansion of early detection tools. Multiple articles confirm >90% accuracy and strong predictive values.